| As part of its case-by-case
preferential pricing policy, a suggestion promoted by MNC’s to withstand
the worldwide campaign for affordable drug prices, GSK has expanded its
offer of cut-price HIV-AIDS and anti-malarial drugs to 63 developing countries
including all "least developed countries" as defined by UN.
|